Biotech · Public company · San Carlos, CA, US
Iovance Biotherapeutics, Inc.
Ticker IOVA · SEC CIK 0001425205
Track this companyFree. Adds Iovance Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2520 recruiting or active
Pipeline programs19From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline19
- Lifileucel plus PembrolizumabPhase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab with Optional Crossover PeriodPhase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IOV-3001Phase 2 · Unresectable MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IOV-4001Phase 2 · Unresectable MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IOV-5001Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- LifileucelPhase 2 · SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- LifileucelPhase 2 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- LifileucelPhase 2 · Melanoma (Skin Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- LifileucelPhase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- LN-145Phase 2 · Cervical CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- LN-145Phase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- LN-145Phase 2 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- LN-145 + pembrolizumabPhase 2 · Cervical CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- LN-145-S1Phase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- LN-145/LN-144Phase 1 · Soft Tissue SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- OOS AMTAGVIUnresectable MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerPHASE2 · NOT_YET_RECRUITING · started Apr 26, 2027ClinicalTrials.gov NCT07925333 · fetched Nov 12, 2026
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaPHASE2 · RECRUITING · started Oct 2, 2026ClinicalTrials.gov NCT07741877 · fetched Nov 12, 2026
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced MelanomaEARLY_PHASE1 · NOT_YET_RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07700121 · fetched Nov 12, 2026
- A Study of IOV-5001 in Adults With Advanced Solid TumorsPHASE1_PHASE2 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07743723 · fetched Nov 12, 2026
- Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseasePHASE1 · RECRUITING · started Jun 3, 2026ClinicalTrials.gov NCT07192900 · fetched Nov 12, 2026
- TIL Therapy in cSCC and MCCPHASE2 · RECRUITING · started Feb 10, 2026ClinicalTrials.gov NCT07288073 · fetched Nov 12, 2026
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 28, 2025ClinicalTrials.gov NCT07288203 · fetched Nov 12, 2026
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersPHASE1_PHASE2 · RECRUITING · started Aug 11, 2025ClinicalTrials.gov NCT05639972 · fetched Nov 12, 2026
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelPHASE1_PHASE2 · RECRUITING · started Mar 11, 2025ClinicalTrials.gov NCT06940739 · fetched Nov 12, 2026
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.PHASE2 · RECRUITING · started Oct 29, 2024ClinicalTrials.gov NCT06481592 · fetched Nov 12, 2026
- Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsPHASE1 · TERMINATED · started Mar 28, 2024ClinicalTrials.gov NCT06566092 · fetched Nov 12, 2026
- Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaPHASE2 · COMPLETED · started Dec 21, 2023ClinicalTrials.gov NCT06151847 · fetched Nov 12, 2026
- Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.PHASE3 · RECRUITING · started Mar 30, 2023ClinicalTrials.gov NCT05727904 · fetched Nov 12, 2026
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersPHASE2 · RECRUITING · started Mar 7, 2023ClinicalTrials.gov NCT05686226 · fetched Nov 12, 2026
- A Study of LN-144 in People With Metastatic Melanoma to the BrainPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 25, 2022ClinicalTrials.gov NCT05640193 · fetched Nov 12, 2026
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or AngiosarcomaPHASE1 · RECRUITING · started Nov 1, 2022ClinicalTrials.gov NCT05607095 · fetched Nov 12, 2026
- KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerPHASE1 · RECRUITING · started Sep 26, 2022ClinicalTrials.gov NCT05483491 · fetched Nov 12, 2026
- A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerPHASE1_PHASE2 · RECRUITING · started Jul 20, 2022ClinicalTrials.gov NCT05361174 · fetched Nov 12, 2026
- Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 1, 2022ClinicalTrials.gov NCT05176470 · fetched Nov 12, 2026
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerPHASE2 · RECRUITING · started May 7, 2021ClinicalTrials.gov NCT04614103 · fetched Nov 12, 2026
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsPHASE2 · TERMINATED · started May 7, 2019ClinicalTrials.gov NCT03645928 · fetched Nov 12, 2026
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 27, 2018ClinicalTrials.gov NCT03449108 · fetched Nov 12, 2026
- Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaPHASE2 · TERMINATED · started Jun 22, 2017ClinicalTrials.gov NCT03108495 · fetched Nov 12, 2026
- Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-DiseasePHASE1 · ACTIVE_NOT_RECRUITING · started Nov 1, 2013ClinicalTrials.gov NCT01937468 · fetched Nov 12, 2026
- Expanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseAVAILABLEClinicalTrials.gov NCT05398640 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026